25th Oct 2006 07:00
24 October 2006Shire plc (the "Company")The Company announces that it was notified on 24 October 2006 under Sections198 to 203 of the Companies Act that, at close of business on 20 October 2006,The Goldman Sachs Group, Inc., was interested in 19,107,594 ordinary shares of‚£0.05p each in the capital of the Company. This holding represents 3.80 percent of the issued ordinary share capital of the Company.Of these 19,107,594 shares: a. The interest in 3,307,493 shares arose from the interest held by Goldman, Sachs & Co. ("GS&Co."), a wholly owned direct subsidiary of GS Inc., acting as custodian for its customers. b. The interest in 5,601,013 shares arose from a beneficial interest held by Goldman Sachs International ("GSI"), a wholly owned indirect subsidiary of GS Inc. c. The interest in 9,959,418 shares arose from the interest held by GS&Co., acting as custodian of 3,319,806 American Depositary Receipts ("ADRs"). d. The interest in 45,513 shares arose from the interest held by GS&Co., acting as discretional manager of 15,171 ADRs. e. The interest in 68,622 shares arose from a beneficial interest in 22,874 ADRs held by GS&Co. f. The interest in 125,532 shares arose from a beneficial interest in 41,844 ADRs held by SLK-Hull Derivatives LLC, a direct subsidiary of GS Inc. g. The interest in 3 shares arose from a beneficial interest in 1 ADR held by Goldman Sachs Financial Markets L.P. T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on attention deficit and hyperactivity disorder (ADHD),human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Thestructure is sufficiently flexible to allow Shire to target new therapeuticareas to the extent opportunities arise through acquisitions. Shire believesthat a carefully selected portfolio of products with a strategically alignedand relatively small-scale sales force will deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire